Januchowski et al. (2016) proved that ATRA treatment in paclitaxel- and topotecan-resistant ovarian cancer cell lines showed a decrease in ALDH1A1 protein levels in a time-dependent manner. The gene discussed is ALDH1A1; the disease is ovarian carcinoma.